Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavlos Msaouel

Showing results (191-200 of 246) with videos related to

Pageof 25
Sort By:
Journal for Immunotherapy of Cancer|March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinomaKabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Cancer Medicine|March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.
JCO Precision Oncology|March 30, 2026
Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite InstabilityMohammad Jad Moussa, Alexander Y Andreev-Drakhlin, Aradhana M Venkatesan, et al.
Journal for Immunotherapy of Cancer|February 12, 2025
Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinomaMohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.
Cancer Medicine|January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary TractMohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.
European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.
Cancer Research Communications|August 5, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology TrialsEsther J Beck, Alexander D Sherry, Marcus A Florez, et al.
Clinical and Translational Medicine|May 25, 2023
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapyDaniel D Shapiro, Niki Millward Zacharias, Durga N Tripathi, et al.
Nature Communications|May 26, 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistanceBujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Pageof 25

Showing results (191-200 of 246) with videos related to

Sort By:
Pageof 25
Journal for Immunotherapy of Cancer|March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinomaKabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Cancer Medicine|March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomesAndrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.
JCO Precision Oncology|March 30, 2026
Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite InstabilityMohammad Jad Moussa, Alexander Y Andreev-Drakhlin, Aradhana M Venkatesan, et al.
Journal for Immunotherapy of Cancer|February 12, 2025
Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinomaMohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, et al.
Cancer Medicine|January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary TractMohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.
European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.
Cancer Research Communications|August 5, 2024
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology TrialsEsther J Beck, Alexander D Sherry, Marcus A Florez, et al.
Clinical and Translational Medicine|May 25, 2023
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapyDaniel D Shapiro, Niki Millward Zacharias, Durga N Tripathi, et al.
Nature Communications|May 26, 2023
SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistanceBujamin H Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi, et al.
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Pageof 25